Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Psyence Australia Pty Ltd
Dana-Farber Cancer Institute
Pfizer
Tizona Therapeutics, Inc
Essen Biotech
Second Life Therapeutics
Novartis
University of Pittsburgh
AstraZeneca
UNC Lineberger Comprehensive Cancer Center
Virginia Commonwealth University
7 Hills Pharma, LLC
Washington University School of Medicine
Fudan University
Institut Claudius Regaud
Genentech, Inc.
DEKA Biosciences
Columbia University
Dana-Farber Cancer Institute
Inhibrx Biosciences, Inc
Hospices Civils de Lyon
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
European Organisation for Research and Treatment of Cancer - EORTC
Cedars-Sinai Medical Center
Celldex Therapeutics
AO GENERIUM
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Kineta Inc.
Eastern Cooperative Oncology Group
Bristol-Myers Squibb
Quadriga Biosciences, Inc.
Ludwig Institute for Cancer Research
Rush University Medical Center
Imperial College London
Roswell Park Cancer Institute
University Hospital, Clermont-Ferrand
Pfizer
National Institutes of Health Clinical Center (CC)
Hospices Civils de Lyon
Shanghai Junshi Bioscience Co., Ltd.
Celgene
Loma Linda University
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
N.N. Petrov National Medical Research Center of Oncology
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Alliance for Clinical Trials in Oncology
Stanford University